List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11492088/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia. Journal of Gastrointestinal Surgery, 2015, 19, 1593-1602.	1.7	196
2	Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. Annals of Surgical Oncology, 2016, 23, 235-243.	1.5	195
3	Association of <i>BRAF</i> Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surgery, 2018, 153, e180996.	4.3	151
4	Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis. Journal of the American College of Surgeons, 2014, 219, 664-675.	0.5	139
5	Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. Journal of Gastrointestinal Surgery, 2015, 19, 1581-1592.	1.7	129
6	Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2016, 23, 2610-2617.	1.5	128
7	The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 4020-4028.	1.5	126
8	Inclusion of Sarcopenia Outperforms the Modified Frailty Index in Predicting 1-Year Mortality among 1,326 Patients Undergoing Gastrointestinal Surgery for a Malignant Indication. Journal of the American College of Surgeons, 2016, 222, 397-407e2.	0.5	120
9	Association Between Specific Mutations in <i>KRAS</i> Codon 12 and Colorectal Liver Metastasis. JAMA Surgery, 2015, 150, 722.	4.3	108
10	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surgery, 2016, 151, 365.	4.3	102
11	Presentation and Clinical Outcomes of Choledochal Cysts in Children and Adults. JAMA Surgery, 2015, 150, 577.	4.3	98
12	Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: A population-based analysis. Journal of Surgical Oncology, 2014, 110, 163-170.	1.7	94
13	Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2015, 150, 538.	4.3	91
14	Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. Journal of Gastrointestinal Surgery, 2014, 18, 2136-2148.	1.7	90
15	Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 4158-4165.	1.5	86
16	Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 991-998.	4.2	83
17	The relative effect of hospital and surgeon volume on failure to rescue among patients undergoing liver resection for cancer. Surgery, 2016, 159, 1004-1012.	1.9	83
18	Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis. Journal of Surgical Oncology, 2017, 116, 643-650.	1.7	80

#	Article	IF	CITATIONS
19	ls Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration. Annals of Surgical Oncology, 2015, 22, 2218-2225.	1.5	78
20	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Annals of Surgical Oncology, 2016, 23, 134-141.	1.5	76
21	Understanding Variation in 30-Day Surgical Readmission in the Era of Accountable Care. JAMA Surgery, 2015, 150, 1042.	4.3	74
22	KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2017, 24, 264-271.	1.5	68
23	Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer. Journal of Surgical Research, 2015, 195, 74-82.	1.6	66
24	Tumor Size Predicts Vascular Invasion and Histologic Grade Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2014, 18, 1284-1291.	1.7	65
25	Frailty as a Risk Predictor of Morbidity and Mortality Following Liver Surgery. Journal of Gastrointestinal Surgery, 2017, 21, 822-830.	1.7	65
26	A Nomogram to Predict Overall Survival and Disease-Free Survival After Curative Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1828-1835.	1.5	62
27	Impact of complications on longâ€ŧerm survival after resection of intrahepatic cholangiocarcinoma. Cancer, 2015, 121, 2730-2739.	4.1	61
28	Conditional Survival after Surgical Resection of Gastric Cancer: A Multi-Institutional Analysis of the US Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 557-564.	1.5	61
29	Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases. Journal of Gastrointestinal Surgery, 2016, 20, 1821-1829.	1.7	61
30	Sarcopenia predicts costs among patients undergoing major abdominal operations. Surgery, 2016, 160, 1162-1171.	1.9	60
31	Identifying Variations in Blood Use Based on Hemoglobin Transfusion Trigger and Target among Hepatopancreaticobiliary Surgeons. Journal of the American College of Surgeons, 2014, 219, 217-228.	0.5	59
32	Use of Endoscopic Ultrasound in the Preoperative Staging of Gastric Cancer: A Multi-Institutional Study of the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 220, 48-56.	0.5	58
33	Impact of Blood Transfusions and Transfusion Practices on Long-Term Outcome Following Hepatopancreaticobiliary Surgery. Journal of Gastrointestinal Surgery, 2015, 19, 887-896.	1.7	57
34	A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. OncoImmunology, 2016, 5, e1083671.	4.6	56
35	Temporal trends in populationâ€based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer, 2014, 120, 3058-3065.	4.1	55
36	Early Versus Late Readmission After Surgery Among Patients With Employer-provided Health Insurance. Annals of Surgery, 2015, 262, 502-511.	4.2	53

YUHREE KIM

#	Article	IF	CITATIONS
37	Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer, 2016, 122, 2698-2707.	4.1	53
38	Modern Interpretation of Giant Cell Tumor of Bone: Predominantly Osteoclastogenic Stromal Tumor. Clinics in Orthopedic Surgery, 2012, 4, 107.	2.2	52
39	Conditional Disease-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors. JAMA Surgery, 2015, 150, 299.	4.3	52
40	Defining Incidence and Risk Factors of Venous Thromboemolism after Hepatectomy. Journal of Gastrointestinal Surgery, 2014, 18, 1116-1124.	1.7	51
41	Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer, 2015, 121, 3564-3573.	4.1	50
42	Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. Annals of Surgical Oncology, 2016, 23, 3736-3743.	1.5	50
43	Effect of Relative Decrease in Blood Hemoglobin Concentrations on Postoperative Morbidity in Patients Who Undergo Major Gastrointestinal Surgery. JAMA Surgery, 2015, 150, 949.	4.3	48
44	Surgical Management of Intrahepatic Cholangiocarcinoma: Defining an Optimal Prognostic Lymph Node Stratification Schema. Annals of Surgical Oncology, 2015, 22, 2772-2778.	1.5	47
45	Long-Term Health-Related Quality of Life after latrogenic Bile Duct Injury Repair. Journal of the American College of Surgeons, 2014, 219, 923-932e10.	0.5	46
46	Patterns of care among patients undergoing hepatic resection: a query of the National Surgical Quality Improvement Program-targeted hepatectomy database. Journal of Surgical Research, 2015, 196, 221-228.	1.6	46
47	The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. Hpb, 2016, 18, 700-705.	0.3	46
48	The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients—A multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 115, 312-318.	1.7	46
49	Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surgery and Nutrition, 2016, 5, 43-52.	1.5	45
50	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2016, 23, 2998-3008.	1.5	44
51	Synchronous primary colorectal and liver metastasis: impact of operative approach on clinical outcomes and hospital charges. Hpb, 2014, 16, 1117-1126.	0.3	43
52	A nationwide analysis of the use and outcomes of perioperative epidural analgesia in patients undergoing hepatic and pancreatic surgery. American Journal of Surgery, 2015, 210, 483-491.	1.8	43
53	Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. Annals of Surgical Oncology, 2016, 23, 3016-3023.	1.5	42
54	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. American Journal of Surgery, 2016, 211, 1106-1113.	1.8	42

#	Article	IF	CITATIONS
55	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. Annals of Surgical Oncology, 2016, 23, 126-133.	1.5	42
56	Clinicopathological features and prognosis of gastric cardia adenocarcinoma: A multiâ€institutional U.S. study. Journal of Surgical Oncology, 2015, 111, 285-292.	1.7	41
57	Readmission incidence and associated factors after a hepatic resection at a major hepato-pancreatico-biliary academic centre. Hpb, 2014, 16, 972-978.	0.3	40
58	The impact of resident involvement onÂsurgical outcomes among patients undergoing hepatic and pancreatic resections. Surgery, 2015, 158, 323-330.	1.9	40
59	Combined resection and RFA in colorectal liver metastases: stratification of long-term outcomes. Journal of Surgical Research, 2016, 206, 182-189.	1.6	38
60	Curative Surgical Resection of Adrenocortical Carcinoma. Annals of Surgery, 2017, 265, 197-204.	4.2	38
61	The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma. World Journal of Surgery, 2015, 39, 1474-1484.	1.6	37
62	Blood loss and outcomes after resection of colorectal liver metastases. Journal of Surgical Research, 2016, 202, 473-480.	1.6	37
63	Venous thromboembolic prophylaxis after a hepatic resection: patterns of care among liver surgeons. Hpb, 2014, 16, 892-898.	0.3	36
64	Potential Economic Impact of Using a Restrictive Transfusion Trigger Among Patients Undergoing Major Abdominal Surgery. JAMA Surgery, 2015, 150, 625.	4.3	35
65	Quality of life after treatment of neuroendocrine liver metastasis. Journal of Surgical Research, 2015, 198, 155-164.	1.6	34
66	Intraoperative Surgical Margin Re-resection for Colorectal Liver Metastasis: Is It Worth the Effort?. Journal of Gastrointestinal Surgery, 2015, 19, 699-707.	1.7	33
67	A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. Journal of Gastrointestinal Surgery, 2016, 20, 1098-1105.	1.7	33
68	Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. Hpb, 2016, 18, 510-517.	0.3	33
69	The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status. Annals of Surgery, 2021, 273, 1165-1172.	4.2	33
70	Lymph node status after resection for gallbladder adenocarcinoma: Prognostic implications of different nodal staging/scoring systems. Journal of Surgical Oncology, 2015, 111, 299-305.	1.7	29
71	Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma. Oncotarget, 2018, 9, 23366-23372.	1.8	29
72	Surgical Management of Advanced Gastrointestinal Stromal Tumors: An International Multi-Institutional Analysis of 158 Patients. Journal of the American College of Surgeons, 2014, 219, 439-449.	0.5	28

#	Article	IF	CITATIONS
73	Factors Associated With Interhospital Variability in Inpatient Costs of Liver and Pancreatic Resections. JAMA Surgery, 2016, 151, 155.	4.3	28
74	National trends in the use of surgery for benign hepatic tumors in the United States. Surgery, 2015, 157, 1055-1064.	1.9	27
75	Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery, 2017, 162, 285-294.	1.9	25
76	Red Cell Transfusion Triggers and Postoperative Outcomes After Major Surgery. Journal of Gastrointestinal Surgery, 2015, 19, 2062-2073.	1.7	24
77	Minimally Invasive Resection of Choledochal Cyst: a Feasible and Safe Surgical Option. Journal of Gastrointestinal Surgery, 2015, 19, 858-865.	1.7	23
78	Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: AÂMarkov decision model. Surgery, 2015, 158, 339-348.	1.9	23
79	Associations Between Patient Perceptions of Communication, Cure, and Other Patient-Related Factors Regarding Patient-Reported Quality of Care Following Surgical Resection of Lung and Colorectal Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 812-826.	1.7	23
80	Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. Annals of Surgical Oncology, 2016, 23, 4401-4409.	1.5	22
81	Age of Transfused Blood Impacts Perioperative Outcomes Among Patients Who Undergo Major Gastrointestinal Surgery. Annals of Surgery, 2017, 265, 103-110.	4.2	22
82	Impact of External-Beam Radiation Therapy on Outcomes Among Patients with Resected Gastric Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2014, 21, 3412-3421.	1.5	20
83	Effect of surgeon and anesthesiologist volume on surgical outcomes. Journal of Surgical Research, 2016, 200, 427-434.	1.6	18
84	A Multi-institutional Analysis of Open Versus Minimally-Invasive Surgery for Gastric Adenocarcinoma: Results of the US Gastric Cancer Collaborative. Journal of Gastrointestinal Surgery, 2014, 18, 1563-1574.	1.7	17
85	Complication timing impacts 30-d mortality after hepatectomy. Journal of Surgical Research, 2016, 203, 495-506.	1.6	17
86	Association of High-Sensitivity Cardiac Troponin T and Natriuretic Peptide With Incident ESRD: The Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2015, 65, 550-558.	1.9	16
87	Early versus late hospital readmission after pancreaticoduodenectomy. Journal of Surgical Research, 2015, 196, 74-81.	1.6	16
88	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Longâ€Term Survival. World Journal of Surgery, 2016, 40, 706-714.	1.6	15
89	Sex- and age-based variation inÂtransfusion practices among patients undergoing major surgery. Surgery, 2015, 158, 1372-1381.	1.9	14
90	A crossâ€sectional study of patient and provider perception of "cure―as a goal of cancer surgery. Journal of Surgical Oncology, 2016, 114, 677-683.	1.7	13

#	Article	IF	CITATIONS
91	Understanding drivers of hospital charge variation for episodes of care among patients undergoing hepatopancreatobiliary surgery. Hpb, 2015, 17, 955-963.	0.3	12
92	Packed red blood cell transfusion after surgery: are we "overtranfusing―our patients?. American Journal of Surgery, 2016, 212, 1-9.	1.8	12
93	Crystalloid administration among patients undergoing liver surgery: Defining patient- and provider-level variation. Surgery, 2016, 159, 389-398.	1.9	12
94	Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases. Journal of Surgical Oncology, 2016, 114, 361-367.	1.7	11
95	Liver regeneration after major liver hepatectomy: Impact of body mass index. Surgery, 2016, 160, 81-91.	1.9	11
96	Perioperative Hyperglycemia and Postoperative Outcomes in Patients Undergoing Resection of Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2017, 21, 228-237.	1.7	11
97	Variation in the use of type and crossmatch blood ordering among patients undergoing hepatic and pancreatic resections. Surgery, 2016, 159, 908-918.	1.9	9
98	Variation in crystalloid administration: an analysis of 6248 patients undergoing major elective surgery. Journal of Surgical Research, 2016, 203, 368-377.	1.6	9
99	Impact of Perioperative Phosphorus and Glucose Levels on Liver Regeneration and Long-term Outcomes after Major Liver Resection. Journal of Gastrointestinal Surgery, 2016, 20, 1305-1316.	1.7	8
100	Variation in inpatient hospital and physician payments among patients undergoing general versus orthopedic operations. Surgery, 2016, 160, 1657-1665.	1.9	6
101	Hospital readmission after multiple major operative procedures among patients withÂemployer provided healthÂinsurance. Surgery, 2016, 160, 178-190.	1.9	6
102	Understanding recurrent readmission after major surgery among patients with employer-provided health insurance. American Journal of Surgery, 2016, 212, 305-314.e2.	1.8	4
103	High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study. Clinical Chemistry, 2021, 67, 298-307.	3.2	4
104	Tumor-Induced Osteomalacia Secondary to a Fibroblast Growth Factor 23-Secreting Phosphaturic Mesenchymal Tumor in the Foot. JBJS Case Connector, 2014, 4, e22.	0.3	2
105	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. Journal of Gastrointestinal Surgery, 2015, 19, 2154-2161.	1.7	2
106	Reply to: epidural analgesia utilization rate for hepatic and pancreatic surgery, that low?. American Journal of Surgery, 2016, 211, 973.	1.8	1
107	Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. , 2015, 121, 3564.		1
108	Reply to patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer, 2015, 121, 4444-4445.	4.1	0

YUHREE KIM

#	Article	IF	CITATIONS
109	Choosing a cancer surgeon: Analyzing factors in patient decision making using a best-worst scaling methodology Journal of Clinical Oncology, 2014, 32, 6551-6551.	1.6	0
110	Difference in outcomes among patients undergoing open versus laparoscopy-assisted approach for gastric cancer: A multi-institutional analysis Journal of Clinical Oncology, 2014, 32, 4082-4082.	1.6	0
111	Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: A multi-institutional analysis Journal of Clinical Oncology, 2014, 32, 4011-4011.	1.6	0
112	Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative intent surgical resection Journal of Clinical Oncology, 2015, 33, 349-349.	1.6	0
113	Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary cancers Journal of Clinical Oncology, 2015, 33, 378-378.	1.6	0
114	Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases Journal of Clinical Oncology, 2015, 33, 282-282.	1.6	0
115	Optimal prognostic lymph node staging system for gallbladder adenocarcinoma: A multi-institutional study Journal of Clinical Oncology, 2016, 34, 364-364.	1.6	0